Arrowhead Pharmaceuticals (ARWR) Expected to Post Earnings of -$0.18 Per Share

Analysts predict that Arrowhead Pharmaceuticals (NASDAQ:ARWR) will report earnings of ($0.18) per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Arrowhead Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.21). Arrowhead Pharmaceuticals reported earnings of ($0.08) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 125%. The firm is expected to announce its next earnings report on Wednesday, May 2nd.

According to Zacks, analysts expect that Arrowhead Pharmaceuticals will report full-year earnings of ($0.71) per share for the current financial year, with EPS estimates ranging from ($0.85) to ($0.56). For the next financial year, analysts forecast that the company will report earnings of ($0.51) per share, with EPS estimates ranging from ($1.01) to $0.90. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Arrowhead Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Friday, February 9th. The biotechnology company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.04). The business had revenue of $3.51 million for the quarter, compared to the consensus estimate of $8.71 million. Arrowhead Pharmaceuticals had a negative return on equity of 42.52% and a negative net margin of 116.17%.

Several analysts have recently commented on the company. ValuEngine upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. B. Riley raised their price target on Arrowhead Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Monday, February 12th. Chardan Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, February 19th. BidaskClub cut Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 14th. Finally, Jefferies Group assumed coverage on Arrowhead Pharmaceuticals in a report on Tuesday, March 27th. They issued a “buy” rating and a $10.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $6.30.

In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, March 27th. The stock was sold at an average price of $8.00, for a total transaction of $160,000.00. Following the transaction, the chief financial officer now owns 330,815 shares in the company, valued at $2,646,520. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Christopher Richard Anzalone sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $7.43, for a total value of $743,000.00. Following the transaction, the chief executive officer now owns 2,194,789 shares in the company, valued at approximately $16,307,282.27. The disclosure for this sale can be found here. In the last quarter, insiders sold 440,000 shares of company stock worth $3,266,600. 4.60% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of ARWR. OppenheimerFunds Inc. boosted its holdings in Arrowhead Pharmaceuticals by 110.0% during the fourth quarter. OppenheimerFunds Inc. now owns 6,300,000 shares of the biotechnology company’s stock worth $23,184,000 after buying an additional 3,300,000 shares during the last quarter. First Manhattan Co. bought a new position in Arrowhead Pharmaceuticals during the fourth quarter worth about $11,707,000. Allianz Asset Management GmbH bought a new position in Arrowhead Pharmaceuticals during the third quarter worth about $1,958,000. Goldman Sachs Group Inc. boosted its holdings in Arrowhead Pharmaceuticals by 297.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 173,078 shares of the biotechnology company’s stock worth $637,000 after buying an additional 129,488 shares during the last quarter. Finally, Alps Advisors Inc. bought a new position in Arrowhead Pharmaceuticals during the fourth quarter worth about $305,000. Hedge funds and other institutional investors own 26.88% of the company’s stock.

Shares of ARWR stock traded up $0.16 during trading hours on Friday, hitting $7.01. 715,595 shares of the company’s stock were exchanged, compared to its average volume of 1,827,772. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.87 and a current ratio of 3.87. The stock has a market capitalization of $593.62, a PE ratio of -14.91 and a beta of 2.36. Arrowhead Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $8.09.

TRADEMARK VIOLATION NOTICE: This news story was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://ledgergazette.com/2018/04/18/arrowhead-pharmaceuticals-arwr-expected-to-post-earnings-of-0-18-per-share.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply